Enzo

The decline matched the struggles of the broader stock market, though bright spots could be found with GenMark, Quidel, and NanoString all having good months.

The firm said the increase in overall revenues was due largely to a 4 percent increase in clinical labs revenues, while product revenues inched up 1 percent year over year.

The Index underperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index, reversing gains it had made in October and November.

The company said the revenue growth was largely due to double-digit growth in its clinical labs business.

The test is performed on the company's AmpiProbe platform, and the approval expands Enzo's offering of infectious disease tests in New York.

The index gained 1 percent, outperforming the Nasdaq Biotechnology Index, but underperforming the Dow, which gained 2 percent.

The increase was largely due to a 13 percent rise in clinical lab revenues, driven by sales of molecular diagnostic tests, particularly in women's health.

Enzo Biochem, Enzo Life Sciences, and Yale University had originally brought the suit against Life Technologies, now part of Thermo Fisher, in 2004.

The Index gained 2 percent in June, outperforming the Dow and the Nasdaq, but underperforming the Nasdaq Biotechnology Index, which gained nearly 9 percent.

Enzo's patent relates to modified nucleotides for diagnostic and therapeutic applications, and is central to separate ongoing lawsuits with diagnostic developers.